The Treasury Department’s proposed restrictions on U.S. investment in Chinese biopharma collide with Beijing’s new export curbs on cutting edge biotech innovations.
Trending
- Top candidates to replace Kurt Suzuki as Angels manager
- Why Charles Huff is the clear choice to be Maryland’s next head coach
- Big Ten football history: Recalling the most obscure opponent of all 18 teams
- Will an ‘edgy’ Arch Manning save Texas’ CFP hopes in SEC clash vs. Ole Miss?
- Oregon reportedly makes starting QB decision ahead of Illinois game
- Has Atlanta’s offense been left behind by a new wave in baseball?
- 2026 Atlanta Braves Player Review: Connor Thomas
- The 10 most unlucky moments for Atlanta Braves hitters in 2026